Rodrigo Paredes de la Fuente

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

Advanced Non Small Cell Lung Cancer

Top Venues

BMJ case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Rodrigo Paredes de la Fuente, Santiago Sucre, Cristina Ponce, Ahmed Anwer Ali Rattani, Mary Linton B Peters
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers 16 (15) (2024)
Rodrigo Paredes de la Fuente, Santiago Sucre, Cristina Ponce, Ahmed Anwer Ali Rattani, Mary Linton B Peters
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers 16 (15) (2024)
Rodrigo Paredes de la Fuente, Santiago Sucre, Cristina Ponce, Ahmed Anwer Ali Rattani, Mary Linton B Peters
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers 16 (15) (2024)
Rodrigo Paredes de la Fuente, James W Doolin, Mary Linton B Peters
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. BMJ case reports 16 (2) (2023)
Rodrigo Paredes de la Fuente, James W Doolin, Mary Linton B Peters
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. BMJ case reports 16 (2) (2023)
Rodrigo Paredes de la Fuente, James W Doolin, Mary Linton B Peters
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. BMJ case reports 16 (2) (2023)